In a phase II study, ibrutinib (Imbruvica) demonstrated clinically meaningful and durable responses and reduced symptom severity, with an overall response rate of 67% in patients with cGVHD.
The socioeconomic status of cell donors affects the health outcomes of blood cancer patients who underwent hematopoietic cell transplantation, according to a new study led by researchers at the University of Minnesota Medical School.
